ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Fujifilm launches full-fledged regenerative medicine business

TOKYO -- Fujifilm Holdings is moving to give regenerative medicine greater status within the group as it targets sales of more than 20 billion yen ($194 million) in this field for 2018.

The office now in charge of the business will be upgraded to a division following Wednesday's general shareholders meeting, allowing for speedier decision-making in areas such as capital spending and management of acquired subsidiaries. The staff has grown from 50 to around 450 since the office was established in 2013.

Fujifilm bought U.S. regenerative medicine startup Cellular Dynamics International last year. That company has extended its reach through such moves as a contract with Swiss health-care group Roche to provide cells for use in drug discovery. Fujifilm intends to focus its expansion into regenerative medicine on supporting drug discovery.

Fujifilm this month revamped the management of Japan Tissue Engineering, which develops regenerative treatments for skin and cartilage, to try to move that subsidiary into the black.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media